Skyrizi 150 mg

SKYRIZI 150 MG is a subcutaneous solution containing risankizumab, used for managing moderate to severe plaque psoriasis. This biologic therapy targets specific immune responses to help reduce skin inflammation.

SKYRIZI 150 MG is primarily used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Risankizumab works by targeting specific proteins involved in the immune response, helping to reduce inflammation and skin symptoms associated with psoriasis. This medication is often considered when other treatments have not been effective or are not suitable.

Common effects of SKYRIZI 150 MG may include reactions at the injection site, such as redness, itching, or pain. Some individuals may also experience upper respiratory infections, fatigue, or headache. These effects are generally mild to moderate and may resolve over time. Always consult a healthcare provider for personalized advice.

SKYRIZI 150 MG should be used with caution in individuals with a history of infections or allergic reactions to biologic therapies. It is important to follow proper handling and storage instructions to maintain the medication's effectiveness. Always inform your healthcare provider about any existing medical conditions or medications you are taking.

SKYRIZI 150 MG may interact with other medications that affect the immune system. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the body's response to risankizumab, so it is advisable to consult a healthcare professional for personalized advice.